Pharmacometabolomics Identifies Candidate Predictor Metabolites of an L-carnitine Treatment Mortality Benefit in Septic Shock
Authors:
- Michael A. PuskarichMPMichael A. Puskarich
- Theodore S. JennaroTJTheodore S. Jennaro
- Christopher E. GilliesCGChristopher E. Gillies
- Charles R. EvansCECharles R. Evans
- Alla KarnovskyAKAlla Karnovsky
- Cora E. McHughCMCora E. McHugh
- Thomas L. FlottTFThomas L. Flott
- Alan E. JonesAJAlan E. Jones
- Kathleen A. StringerKSKathleen A. Stringer
Preprint
Abstract
Background: Sepsis-induced metabolic dysfunction contributes to organ failure and death. L-carnitine has shown promise for septic shock, but a recent study demonstrated a non-significant reduction in mortality. Methods: A pharmacometabolomics study of patients (n=250) in a Phase II trial of L-carnitine to identify metabolic profiles predictive of a 90-day mortality benefit from L-carnitine. The independent predictive value of each pre-treatment metabolite concentration, adjusted for L-carnitine dose, on 90-day mortality was determined by logistic regression. A grid-search analysis maximizing the Z-statistic from a binomial proportion test identified specific metabolite threshold levels that discriminated L-carnitine responsive patients. Threshold concentrations were further assessed by hazard-ratio and Kaplan-Meier estimate. Findings: Accounting for L-carnitine treatment and dose, 11 1 H-NMR metabolites and 12 acylcarnitines were independent predictors of 90-day mortality. Based on the grid-search analysis numerous acylcarnitines and valine were identified as candidate metabolites of drug response. Acetylcarnitine emerged as highly viable for the prediction of an L-carnitine mortality benefit due to its abundance and biological relevance. Using its most statistically significant threshold concentration, patients with acetylcarnitine ≥35µM were less likely to die at 90 days if treated with L-carnitine (18 g) versus placebo (p=0.01 by log rank test). Interpretation: Metabolomics identified independent predictors of 90-day sepsis mortality. Our proof-of-concept approach shows how pharmacometabolomics may be useful for tackling the heterogeneity of sepsis and informing clinical trial design. Also, metabolomics can help understand mechanisms of sepsis heterogeneity and variable drug response, since sepsis induces alterations in numerous metabolite concentrations.Keywords
All Related Versions
- Published version: Clinical and Translational Science, 14 (6), 2288.
This publication has 46 references indexed in Scilit:
- Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease StudyThe Lancet, 2020
- Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for SepsisJAMA, 2019
- Nuclear magnetic resonance-based serum metabolomic analysis reveals different disease evolution profiles between septic shock survivors and non-survivorsCritical Care, 2019
- Heterogeneity in sepsis: new biological evidence with clinical applicationsCritical Care, 2019
- Plasma mitochondrial DNA and metabolomic alterations in severe critical illnessCritical Care, 2018
- Toward Smarter Lumping and Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome Clinical Trial DesignAmerican Journal of Respiratory and Critical Care Medicine, 2016
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)JAMA, 2016
- Assessment of Global Incidence and Mortality of Hospital-treated Sepsis: Current Estimates and LimitationsAmerican Journal of Respiratory and Critical Care Medicine, 2016
- Integrative “Omic” Analysis of Experimental Bacteremia Identifies a Metabolic Signature That Distinguishes Human Sepsis from Systemic Inflammatory Response SyndromesAmerican Journal of Respiratory and Critical Care Medicine, 2014
- Benchmarking the Incidence and Mortality of Severe Sepsis in the United States*Critical Care Medicine, 2013